Itaconate, a metabolite of the tricarboxylic acid cycle, plays anti-inflammatory roles in macrophages during endotoxemia. The mechanisms underlying its anti-inflammatory roles have been shown to be mediated by the modulation of oxidative stress, an important mechanism of hepatic ischemiareperfusion (I/R) injury. However, the role of itaconate in liver I/R injury is unknown. Here we found that deletion of immune-responsive gene 1 (IRG1), encoding for the enzyme producing itaconate, exacerbated liver injury and systemic inflammation. Furthermore, bone marrow adoptive transfer experiments indicated that deletion of IRG1 in both hematopoietic and non-hematopoietic compartments contributes to the protection mediated by IRG1 after I/R. Interestingly, the expression of IRG1 was up-regulated in hepatocytes after I/R and hypoxia/reoxygenation (H/R)-induced oxidative stress. Modulation of the IRG1 expression levels in hepatocytes regulated hepatocyte cell death. Importantly, addition of 4-octyl itaconate (4-OI) significantly improved liver injury and
and NAD(P)H: quinone oxidoreductase 1 (NQO1), as well as other cytoprotective pathways. (18, 19) Previous studies have demonstrated that the Nrf2 pathway limits oxidant injury in models of I/R. (18, 20) A link between IRG1 and Nrf2 was recently identified when itaconate was shown to directly alkylate cysteine residues in KEAP1, leading to an increase in Nrf2 in macrophages during endotoxemia. (12) In this study, we hypothesized that the IRG1/itaconate pathway would be part of a protective response against oxidant injury in the liver, possibly through the up-regulation of Nrf2. Using IRG1 −/− mice, we found that IRG1 suppresses injury and inflammation during liver I/R and protects cultured hepatocytes from apoptosis following hypoxia/reoxygenation (H/R). Both liver I/R in vivo and hepatocyte H/R in vitro led to the up-regulation of IRG1. The cell-permeable itaconate analogue, 4octyl itaconate (4-OI), protected against liver I/R injury and rescued hepatocytes from H/R-induced apoptosis through a mechanism that required Nrf2. These findings reveal an unrecognized role of the IRG1/itaconate-Nrf2 pathway in antioxidant defenses in hepatocytes during liver I/R.
Methods
Animals. IRG1 knockout (KO) (IRG1 −/− ) mice (The Jackson Laboratory 029340) and Nrf2 KO (Nrf2 −/− ) mice (The Jackson Laboratory 017009) were bred and housed under specific pathogen-free conditions in our facility. C57BL/6NJ (B6N) (#005304) and C57BL/6J (B6J) (#000664) controls were purchased from The Jackson Laboratory. IRG1 −/− animals were congenic to the C57BL/6NJ background, and Nrf2 −/− animals were congenic to the C57BL/6J background. Male mice aged 8 to 12 weeks, weighing 21 to 30 g, were used in our experiments. All experimental protocols were approved by the Institutional Animal Use and Care Committee of the University of Pittsburgh. The experiments were performed in accordance with National Institutes of Health guidelines for the use of laboratory animals.
Mouse liver I/R injury model and animal treatment. A nonlethal model of segmental (70%)
hepatic warm I/R was used as described. (21) Briefly, all structures in the portal triad (hepatic artery, portal vein, bile duct) to the left and median liver lobes were occluded with a microvascular clamp for 60 minutes, and then reperfusion was initiated by clamp removal. Ambient temperature of the mice
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This article is protected by copyright. All rights reserved during ischemia was maintained at 33°C using an incubator chamber. Sham-operated animals underwent anesthesia, laparotomy, and exposure of the portal triad without hepatic ischemia. Animals were sacrificed at predetermined time points after reperfusion. For 4-OI (Cayman Chemical) administration, mice were treated intraperitoneally (IP) with 4-OI (25 mg/kg/dose) in (2- hydroxypropyl)-β-cyclodextrin in phosphate-buffered saline (PBS) or vehicle control 2 hours before hepatic ischemia and at the time of reperfusion.
Reagents. The following reagents were used: mouse IRG1 enzyme-linked immunosorbent assay Encapsula NanoSciences) 24 hours prior to irradiation. Recipient mice were then exposed to an otherwise lethal 1000 cGy from a Cesium source (Nordion International) 6 hours before receiving 5 × 10 6 bone marrow cells by tail vein injection. The bone marrow cells were prepared in a sterile manner from the tibia and femur bones of the donor mice. All animals were monitored three times weekly for the first 2 weeks to ensure successful bone marrow engraftment. The chimeric mice underwent hepatic I/R after 8 to 12 weeks to ensure stable engraftment.
Hepatocyte and nonparenchymal cell isolation and treatment. Mice were perfused by an in situ collagenase (type VI; Sigma) technique. Hepatocytes were separated from nonparenchymal cells (NPCs) by two steps of differential centrifugation. Hepatocyte purity exceeded 99% as measured by light microscopy. The cell viability was typically more than 95% as measured by trypan blue exclusion. NPCs were isolated and subjected to differential centrifugation and purified without
This article is protected by copyright. All rights reserved hepatocytes as determined by light microscopy. Hepatocytes were plated on gelatin-coated culture plates in Williams' E medium with 10% calf serum, 15 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES), 1 μM insulin, 2 mM L-glutamine, 100 U/mL penicillin, and 100 U/mL streptomycin. Cells were allowed to attach overnight. Medium was replaced with fresh medium before stimulation. To simulate ischemia, hepatocytes were cultured under the hypoxic condition (1% oxygen) in an atmosphere-controlled chamber (MIC-101, patent no. 5352414) containing a gas mixture composed of 94% N 2 , 5% CO 2 , and 1% O 2 . Cells were then reoxygenated under normoxic conditions in the standard cell culture incubator.
Isolation of human hepatocytes. Human hepatocytes were isolated from histologically normal liver and were provided by David A. Geller (Department of Surgery, University of Pittsburgh) according to a protocol approved by the institutional review board. Human hepatocytes were prepared by a threestep collagenase perfusion technique, as described. (22) Isolated human hepatocytes were cultured in Williams' E medium supplemented with 5% calf serum, 100 U/mL penicillin, 100 U/mL streptomycin, 2 mM L-glutamine, and 15 mM HEPES.
Alanine aminotransferase and cytokine abundance assessment. Alanine aminotransferase (ALT) levels were determined by the DRI-CHEM 4000 Chemistry Analyzer System (Heska). Cytokine abundance was analyzed by ELISA specific for interleukin (IL)-6 (R&D Systems) in the plasma according to the manufacturer's instructions.
Myeloperoxidase assay.
A part of the ischemic liver lobe was homogenized, and myeloperoxidase (MPO) was quantified using a mouse MPO ELISA kit (Hycult Biotechnology) according to the manufacturer's instructions.
Histological analysis. Tissue samples were harvested and processed for hematoxylin and eosin (H&E) as described. (23) Samples were imaged and scored using the Suzuki methodology by three independent members from the Center for Biologic Imaging (University of Pittsburgh). The tissues were assessed for the amount (%) of inflammation (sinusoidal congestion, cytoplasmic vacuolization, infiltrating inflammatory cells) and necrosis for characterizing liver damage after I/R.
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This article is protected by copyright. All rights reserved Immunofluorescence. Liver samples were processed as described. (24) In brief, sections of 6 μm were permeabilized with 0.1% Triton X-100 for 20 minutes, rehydrated with 5 washes of PBS + 0.5% bovine serum albumin (BSA) (PBB), and then the tissue sections underwent a blocking step of 45 minutes with PBS + 20% normal goat serum (NGS). Samples were incubated with primary antibodies (anti-4-hydroxynonenal [4-HNE] at 1:100, Millipore #393207; anti-lymphocyte antigen 6G [Ly6G] at 1:100, BD Biosciences #560599; anti-F4/80 at 1:250, BD Biosciences #552958) in PBB + 0.1 Triton X-100 for 12 hours or TMR Red (1:1000, Roche #12156792910) for 1 hour at room temperature. All immunofluorescent experiments staining sets involved staining β-actin and nuclear stain for use in quantitation. Imaging conditions were maintained at identical settings within each antibody-labeling experiment with original gating performed using the primary depletion control. Large area images equivalent to nine unique fields were taken in X and Y with a Nikon A1 confocal microscope (purchased with 1S10OD019973-01 awarded to Dr. Simon C. Watkins). Quantification was performed using NIS Elements (Nikon, Melville, NY).
Western blot. Samples were lysed in lysis buffer (Cell Signaling Technology) with protease inhibitors and centrifuged at 16,000g for 10 minutes, and supernatant was collected. Protein concentrations of the supernatants were determined with BCA assay kit (Thermo Fisher Scientific).
Denatured protein samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a polyvinylidene difluoride membrane at 250 mA for 2 hours. The membrane was blocked in 5% milk (Bio-Rad) for 1 hour and then incubated overnight with primary antibody in 1% milk. Membranes were washed three times in Trishydroxymethylaminomethane-buffered saline Tween (TBST) for 10 minutes, incubated with horseradish peroxidase-conjugated secondary antibody for 1 hour, and then washed three times for 10 minutes in TBS-T before being developed for chemiluminescence (Bio-Rad). Western images were quantified by densitometry using ImageJ software. Mouse IRG1 plasmid transfections. pCMV6-Myc-IRG1 overexpressing plasmid (5 μg, mouse IRG1 transfection-ready DNA; OriGene) was transfected into 1 × 10 6 hepatocytes using
This article is protected by copyright. All rights reserved Lipofectamine 3000 Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's protocol. The DNA-lipid complex was added to cells and incubated for 36 hours.
Nuclear protein extraction. The nuclear extraction was performed using an NE-PER Nuclear
Cytoplasmic Extraction Reagent kit (Thermo Fisher Scientific) according to the manufacturer's instruction.
Statistics. Results were shown as mean ± standard deviation (SD) from at least three independent experiments. Data were analyzed by GraphPad Prism 7 software. Comparisons between two experimental groups were performed by 2-tailed Student t test. Analysis of three or more independent groups was performed by 1-way analysis of variance (ANOVA). P < 0.05 was considered statistically significant.
Results

Deletion of IRG1 worsens liver injury after I/R.
To study the role of IRG1 and itaconate in hepatic I/R injury, IRG1 −/− mice and control WT mice (C57BL/6NJ) were subjected to warm liver I/R with 1 hour of ischemia followed by 0, 6, or 24 hours of reperfusion ( Fig. 1 A,B ,C). Notably, IRG1 −/− mice that are defective in producing itaconate showed exacerbated liver injury at both 6 and 24 hours after reperfusion, as demonstrated by significantly higher levels of serum ALT than those of control mice ( Fig. 1B,C ). Histological analysis showed significantly larger necrotic areas in liver sections of IRG1 −/− mice after 6 and 24 hours of reperfusion ( Fig. 1D ,E), and this was associated with higher Suzuki's liver injury scores ( Fig. 1F ). However, there was no significant difference in hepatic damage between WT and IRG1 −/− mice after 1 hour of ischemia but no reperfusion ( Fig. 1A ,D,E), indicating that IRG1 mainly protects the liver from the injury that occurs during the reperfusion phase of hepatic I/R. We also confirmed that IRG1 mRNA expression was up-regulated in the livers of WT mice subjected to I/R (Fig. 1G ), and as expected, we observed significantly higher levels of itaconate in the livers of mice after I/R ( Figure 1H ). Together, these indicate that IRG1 is up-regulated in the setting of noninfectious inflammation in the liver.
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Increased systemic inflammation and hepatic infiltration of inflammatory cells in IRG1 −/− mice after I/R.
The pathogenesis of liver I/R injury includes both direct cellular damage as a result of the oxidative stress as well as injury resulting from activation of inflammatory pathways. (25) Studies have shown that itaconate plays anti-inflammatory roles in inflammatory macrophages during endotoxemia. (12) Interestingly, we found that deletion of IRG1 led to increased systemic and local inflammation after hepatic I/R, as assessed by higher levels of both plasma IL-6 and hepatic IL-6 mRNA expression in IRG1 −/− mice compared to control WT mice (C57BL/6NJ) ( Fig. 2A,B ). Levels of MCP-1 and Ly6G mRNA, as well as MPO protein levels were significantly higher in the livers of IRG1 −/− mice than control mice after I/R ( 
Deletion of IRG1 in either hematopoietic or non-hematopoietic compartments increases liver injury.
IRG1 expression is well characterized in myeloid cells. (7, 26) However, multiple cell types participate in the adaptive and maladaptive responses in the liver to I/R. Surprisingly, we found that IRG1 expression was up-regulated in both hepatocytes and NPCs from WT mice subjected to I/R (Fig. 3A ).
To determine if bone marrow-derived cells and/or non-bone marrow-derived cells were involved in the IRG1-mediated protection from hepatic I/R injury, we generated bone marrow chimeras by adoptive transfer of donor bone marrow cells into irradiated recipient mice using the following combinations of WT (C57BL/6NJ) and IRG1 −/− (KO) mice (recipient/donor): WT/WT, WT/KO, KO/WT, KO/KO. Chimeric mice underwent hepatic I/R 8 to 12 weeks after adoptive transfer. Liver injury was assessed by measuring serum ALT and area of necrosis in liver sections stained with H&E.
Surprisingly, WT recipients receiving IRG1 −/− bone marrow cells (WT/KO) as well as IRG1 −/− mice receiving WT bone marrow cells (KO/WT) had higher ALT levels and worse necrosis than WT/WT
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This article is protected by copyright. All rights reserved mice ( Fig. 3B-D) . Importantly, KO/KO mice exhibited the most severe liver injury after I/R among the chimeric groups ( Fig. 3B-D) , indicating that deletion of IRG1 in both hematopoietic and nonhematopoietic compartments contributes to the protection mediated by IRG1 after I/R. We also confirmed significantly lower itaconate levels in the livers of WT/KO, KO/WT and KO/KO chimeras after I/R than those of WT/WT mice (Fig. 3E ). Taken together, these observations reveal the regulatory role of IRG1 in immune cells in the setting of liver I/R as well as an unrecognized role of IRG1 in hepatocytes.
IRG1 protects hepatocytes from oxidative cell death in vivo and in vitro.
To further explore the protective role of IRG1 during oxidative stress in liver cells, we first assessed levels of apoptosis in livers and hepatocytes from WT (C57BL/6NJ) and IRG1 −/− mice. As shown in (Fig. 4H ). These findings suggest that IRG1 deficiency renders hepatocytes more susceptible to oxidative stress both in vivo and in vitro.
Itaconate ameliorates hepatic I/R injury and rescues hepatocytes from injury resulting from H/R.
Accepted Article
Having established that IRG1 is part of a protective response to I/R injury, we then sought to determine if the enzymatic product of IRG1, itaconate, also protected the liver from I/R. To do this, we used 4-OI, a recently described synthesized cell-permeable itaconate derivative in our in vivo and in vitro models. (12) Administration of 4-OI in the I/R model significantly reduced hepatic injury in both control (C57BL/6NJ) and IRG1 −/− mice compared with mice subjected to I/R and receiving vehicle treatment. Both the circulating ALT levels and histologic examination of liver necrosis were lower in mice receiving 4-OI at 6 hours of reperfusion ( Fig. 5A-C) . Similarly, 4-OI treatment reduced the apoptotic cell death in livers after I/R compared with vehicle treatment, as determined by lower numbers of TMR-positive cells observed in livers of 4-OI-treated mice (Supporting Fig. 1B ).
Consistent with these in vivo observations, 4-OI significantly reduced LDH release by cultured WT hepatocytes after H/R (Fig. 5D ) in association with less cleaved caspase-3 and caspase-7, as assessed by western blot (Fig. 5E,F) . This hepatocellular protective effect of 4-OI could also be observed in IRG1 −/− hepatocytes subjected to H/R (Fig. 5G,H) . We also found that IRG1 deficient hepatocytes upregulated caspase-3 activation to a greater degree after TNF-α exposure in vitro than WT hepatocytes, suggesting that IRG1 may play a protective role in other settings of liver injury (Supporting Fig. 2A ).
Together, these data show that itaconate can protect hepatocytes from oxidative cell death both in vivo and in vitro.
Deficiency of IRG1 suppressed Nrf2 pathway activation in hepatocytes after oxidative stress.
Nrf2, a master cellular regulator of redox homeostasis, has been shown to protect against liver I/R injury. (19, 20) A recent study suggested that Nrf2 is involved in the anti-inflammatory actions of itaconate in macrophages during endotoxemia. (12) Given these findings, we hypothesized that IRG1mediated hepatoprotection in liver I/R occurs by up-regulation of Nrf2-antioxidant pathways in hepatocytes in the setting of oxidative stress. To test this hypothesis, we first assessed the Nrf2 expression in livers of mice subjected to hepatic I/R. As expected, Nrf2 expression increased in livers of WT (C57BL/6NJ) mice after I/R. In contrast, Nrf2 expression was not increased in livers of IRG1 −/− mice subjected to I/R (Fig. 6A ). In addition, levels of HO-1 and NQO1, both downstream of Nrf2, were lower in livers of IRG1 −/− mice compared with WT mice following I/R (Fig. 6B) .
Importantly, we observed more lipid peroxidation in the livers of IRG1 −/− mice after hepatic I/R than in those of WT mice, as measured by 4-HNE staining (Fig. 6C) . In vitro, we also found lower levels Accepted Article of Nrf2 in hepatocytes isolated from IRG1 −/− mice compared with those from WT mice after H/R (Fig.   6D ). Importantly, the nuclear translocation of Nrf2 was attenuated in IRG1 −/− hepatocytes after H/R (Fig. 6E ). The expression of HO-1 and NQO1 in hepatocytes from IRG1 −/− mice was significantly lower when compared with WT hepatocytes following H/R (Fig. 6F) . Consistent with the in vivo results, ROS generation in IRG1 −/− hepatocytes was found to be significantly higher after H/R compared with WT hepatocytes (Fig. 6G) . These data indicate an important role for IRG1 in regulating antioxidant responses in hepatocytes during I/R.
Itaconate protects hepatocytes against oxidative stress damage in an Nrf2-dependent manner.
We next assessed whether treatment with exogenous itaconate induces Nrf2 activation in hepatocytes during H/R. Pretreatment with 4-OI increased the expression of Nrf2 and its downstream target genes (HO-1 and NQO1) in WT hepatocytes in a dose-dependent manner both under normoxic conditions and after H/R (Fig. 7A,B ) (Supporting Fig. 2B-D) . Similarly, treatment with 4-OI boosted the nuclear translocation of Nrf2 in hepatocytes before and after H/R (Fig. 7C ) (Supporting Fig. 2E ). Furthermore, production of ROS in hepatocytes pretreated with 4-OI was markedly reduced after H/R (Fig. 7D ). To further determine whether 4-OI is protective through a mechanism that is dependent on Nrf2, WT (C57BL/6J) and Nrf2 −/− mice received either 4-OI or vehicle control and then subjected to I/R. As expected, Nrf2 −/− mice exhibited more liver damage than WT mice in the vehicle treated groups, as assessed by a higher level of circulating ALT and greater liver necrosis after I/R (Fig. 7E-G) .
Importantly, 4-OI treatment significantly reduced hepatic injury in WT mice after I/R, however had no effect on I/R-induced liver injury in the Nrf2 −/− mice ( Fig. 7E-G) . Furthermore, this phenomenon was also observed in cultured hepatocytes pretreated with 4-OI in vitro, as assessed by the LDH release by WT (C57BL/6J) and Nrf2 −/− hepatocytes after H/R (Fig. 7H ). In addition, 4-OI treatment did not change the expression of Nrf2 and HO-1 in Nrf2 −/− hepatocytes as seen in WT hepatocytes ( Fig. 7I) (Supporting Fig. 2F,G) , suggesting that the protective effect of 4-OI against oxidative stress damage in hepatocytes is mediated by Nrf2. We also confirmed that 4-OI also increased the expression of Nrf2 and HO-1 in primary human hepatocytes both under normoxic conditions and after H/R (Fig. 7J ) (Supporting Fig. 2H,I) . Taken together, our results indicate that itaconate is an important inducer of Nrf2-mediated antioxidative response in hepatocytes during hepatic I/R injury.
Accepted Article
Discussion
The finding that IRG1 catalyzes the synthesis of itaconate from cis-aconitate identified a novel function for this protein known to be among the most highly induced in the LPS-treated macrophages. (6) Functions ascribed to itaconate include the inhibition of succinate dehydrogenase and the up-regulation of the antioxidant transcription factor, Nrf2. (11, 12) In experiments aimed at determining the role of the IRG1/itaconate pathway in liver I/R, we found that IRG1 is markedly upregulated during liver I/R and in hepatocytes exposed to oxidant stress and that IRG1 and itaconate protected hepatocytes from oxidant-associated cell death. We confirmed that Nrf2 also protects the liver and hepatocytes from ischemic injury and linked the protective effects of IRG1 and itaconate to Nrf2 signaling. These findings show that IRG1 plays critical roles in antioxidant defenses in hepatocytes by Nrf2.
Although IRG1 and itaconate have been well described in macrophages, (27, 28) the expression and functions of this pathway in non-immune cells are largely unknown. IRG1 was found to be highly expressed in the uterine epithelium of mice undergoing early pregnancy (9, 10) where it is important to embryonic implantation. (9) IRG1 expression was also induced in alveolar epithelial cells after respiratory syncytial virus (RSV) infection (29) and in glioma cells. (30) Here we expand the cell types known to express IRG1 by showing that hepatocytes rapidly up-regulate IRG1 in response to H/R.
These results are the first to document the critical role of IRG1 in the acute setting of sterile injury induced by I/R. Whether inducible IRG1 expression is typical of epithelial cells is unknown. IRG1 links cellular metabolism with immune defense by catalyzing itaconic acid production, and metabolic reprogramming is emerging as a key hallmark of innate immunity. (6) In parallel with the enhanced glycolysis, a disrupted TCA cycle is an important feature of inflammatory macrophages where the accumulation of metabolic intermediates, such as citrate, succinate, and itaconate, functions as regulators of inflammatory responses. (31, 32) Isocitrate dehydrogenase (IDH1) expression is inhibited in inflammatory macrophages, and this leads to the accumulation of citrate, which contributes to
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Itaconate has been demonstrated to have anti-inflammatory properties by inhibiting the activity of succinate dehydrogenase, an enzyme critical for driving the inflammatory response by oxidizing succinate. (11, 33) Moreover, a recent study demonstrates that a cell-permeable derivative of itaconate can dampen the sustained inflammatory response through activation of the transcription factor Nrf2. (12) Because IRG1 expression by both bone marrow-derived and non-bone marrow-derived cells contributed to the IRG1-mediated protection in liver I/R, it is likely that the described pathways for IRG1 observed in macrophages contributed to the protection. However, it would seem that an additional important mechanism of protection is through the induction of Nrf2-dependent antioxidant pathways in hepatocytes.
Dimethyl itaconate (DI), a cell membrane-permeable itaconate derivative, has been previously used as an exogenous itaconate surrogate in studies exploring the role of IRG1. (11, 13) However, a recent finding revealed that DI is not metabolized into itaconate within cells. (34) To overcome the limitations of DI, a new cell-permeable itaconate derivative, 4-OI, was developed, making it a suitable cellpermeable itaconate surrogate with which to probe the physiological function of itaconate. (12) In our study, we demonstrated that treatment with 4-OI ameliorated hepatic I/R injury in vivo and rescued hepatocytes from injury resulting from H/R in vitro and thus may provide a basis for the development of 4-OI for the prevention of hepatic I/R injury.
Nrf2 is a transcription factor associated with intracellular signaling that protects organs against oxidative stress. (35) (36) (37) A number of studies indicate that depletion of Nrf2 increases susceptibility to toxin-induced liver injury, (38) (39) (40) all of which provide strong evidence for Nrf2 as a hepatoprotective pathway. Additionally, it has been shown that Nrf2 activation protects the liver from I/R injury in mice. (18, 20, (41) (42) (43) (44) Specifically, the effect of cell-specific Nrf2 induction was also explored, and the activation of the Nrf2-antioxidant response element pathway in either hepatocytes (18, 20, 43) or myeloid cells (44) decreases hepatocellular damage, apoptosis, inflammation, and oxidative stress after hepatic I/R injury. Our work provides support for the recent findings that itaconate can activate Nrf2-driven signaling. (12) Interestingly, we demonstrate that treatment with 4-OI increases the expression and nuclear translocation of Nrf2 as well as up-regulation of its downstream protective pathways (HO-1
This article is protected by copyright. All rights reserved and NQO1), not only in mouse hepatocytes but also in primary human hepatocytes, both under basic conditions and after H/R.
In summary, our study reveals a novel function for IRG1 and its enzymatic product itaconate in regulation of the protective anti-inflammatory and antioxidative responses to liver I/R. Importantly, our study reveals an unappreciated hepatoprotective role of hepatocyte-specific IRG1 during liver I/R injury by activating Nrf2 antioxidative response in hepatocytes. Our study also provides evidence that administration of 4-OI can reduce hepatic I/R injury, and this may be a potential pharmacological strategy to prevent this complication in the clinical setting. 
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